Abstract:Background: The high morbidity and mortality rate of coronary heart disease poses a serious threat to human health. Atherosclerosis, a chronic inflammation of the blood vessel wall, is a significant pathological process leading to coronary heart disease. Macrophage inflammation plays a crucial role in the occurrence and development of atherosclerosis. Methods: Macrophage inflammation model was constructed by lipopolysaccharide (LPS), and macrophages were treated with Celastrol at different concentrations (0, 0.1, 1, 10, 100 ng/mL) and different time points (0, 1, 3, 6, 12 h). Real-time quantitative PCR (qPCR) and Western Blot were used to detect the expression of Nur77 mRNA and protein. Macrophages were then pretreated with 100 nmol/L tripterine for 40min and co-cultured with 100 ng/mL LPS. The expression levels of inflammatory factors and chemokines, phosphorylation of phospho-dynamin-related protein 1 (p-Drp1) at Ser637 and expression of mitochondrial fusion protein tnitochondrial fusion protein mitofusin-2 (Mfn2) were detected by qPCR, Western blot and ELISA, respectively. The changes of mitochondria( membrane potential were detected by JC-1 probe. Results: 100 nmol/L. Celastrol can significantly inhibit LPS-induced inflammatory responses and downregulate the expression levels of cytokines such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX2), tumor necrosis factor-alpha (TNF-alpha), chemokines (CCL-2, and CXCL-10), as well as chemokines. And Celastrol could regulate mitochondrial fission and fusion by promoting the phosphorylation of the Drpl at the Ser637 site, thereby inhibiting mitochondrial fission. M the same time, by up-regulating the level of the Mfn2, Celastrol also promoted mitochondrial fusion. In addition, we found that the nuclear factor-kgene binding (NF-kappa B), extracellular signal-regulated kinase 1/2 (ERK1/2), and p38 signaling pathways aided the drug's anti-inflammatory effects. We also explored the relationship between Celastrol and the nuclear receptor Nur77 and found that it could up-regulate the expression of Nur77. Conclusions: Our study found that Celastrol could reduce inflammation by regulating Drpl dependent mitochondrial fission and fusion, as well as the ERK1/2, p38, NF-kappa B signaling pathways. This finding provides a strong direction for the development of new anti-inflammatory drugs for atherosclerosis.

Celastrol and Its Role in Controlling Chronic Diseases

Control of autoimmune inflammation by celastrol, a natural triterpenoid

Celastrol Inhibits Cancer Metastasis by Suppressing M2-like Polarization of Macrophages.

Molecular targets of celastrol derived from Thunder of God Vine: Potential role in the treatment of inflammatory disorders and cancer

Celastrol Prevents Atherosclerosis Via Inhibiting Lox-1 and Oxidative Stress

Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases

Celastrol: A Promising Agent Fighting against Cardiovascular Diseases

Celastrol ameliorates osteoarthritis via regulating TLR2/NF-κB signaling pathway

Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies

Regulating Mitochondrial Homeostasis and Inhibiting Inflammatory Responses Through Celastrol

Molecular targets of celastrol in cancer: Recent trends and advancements

Celastrol-induced apoptosis in human HaCaT keratinocytes involves the inhibition of NF-κB activity.

Molecular modulators of celastrol as the keystones for its diverse pharmacological activities

Celastrol: An Update on Its Hepatoprotective Properties and the Linked Molecular Mechanisms

Celastrol in metabolic diseases: Progress and application prospects

Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway

Celastrol ameliorates lupus by promoting apoptosis of autoimmune T cells and preventing autoimmune response in MRL/lpr mice

Celastrol: Molecular targets of Thunder God Vine

Celastrol Ameliorates Ulcerative Colitis-Related Colorectal Cancer in Mice via Suppressing Inflammatory Responses and Epithelial-Mesenchymal Transition

Celastrol attenuates pain and cartilage damage via SDF-1/CXCR4 signalling pathway in osteoarthritis rats.

Effective treatment of rat adjuvant-induced arthritis by celastrol